Trials / Completed
CompletedNCT01995071
A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of ABT-493 and ABT-530 in adults with genotype 1 HCV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493 | Tablet |
| DRUG | ABT-530 | Tablet |
| DRUG | ABT-450/r/ABT-267, ABT-333 | Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet |
| DRUG | Ribavirin (RBV) | Tablet |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2013-11-26
- Last updated
- 2021-07-12
- Results posted
- 2017-10-16
Source: ClinicalTrials.gov record NCT01995071. Inclusion in this directory is not an endorsement.